Antinuclear Antibody Test Market Size

Antinuclear Antibody Test Market size was over USD 1.13 Billion in 2023 and is likely to reach USD 5.74 Billion by the end of 2036, witnessing around 13.3% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of antinuclear antibody test is assessed at USD 1.27 Billion. The growth of the market can be attributed to the higher prevalence of autoimmune diseases and the growing number of reagent rental agreements across the globe. According to a report published by World Health Organization (WHO), in 2017, there were 9 million people suffering from type 1 diabetes, while 422 million people in the global population have some sort of diabetes. Moreover, 1.5 million people die due to diabetes every year globally. Autoimmune disorders can be genetic or acquired that cause suppression of the immune system of the patient. The high risk of autoimmune disorders with increasing incidence of viral and bacterial infections among people with suppressed immune systems is estimated to boost the market growth.

Furthermore, rising awareness of the ANA test and increasing use of antibiotics is also projected to propel the growth of the market over the forecast period. Data released by the National Library of Medicine (NLM) in 2020 showed that 587,357 ANA tests were conducted while 437,966 patients took ANA tests worldwide. In modern times, both technology and awareness of health are growing exponentially. Hence, all these factors are anticipated to hike the growth of the market during the forecast period. The increasing spending capacity of people on healthcare needs and basic medical treatment is also estimated to propel market growth.